Gilead and Compugen enter exclusive license agreement for immunotherapy programme
December 20, 2023Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …
Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics
December 20, 2023Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …
BioNTech achieves milestone at vaccine manufacturing site in Rwanda
December 19, 2023Manufacturing and Production BioNTech, Immunology, manufacturing, rwanda
BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
December 18, 2023Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
FDA approves Glaukos’ iDose TR treatment for glaucoma disease
December 15, 2023Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma
Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …
First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617
December 15, 2023Research and Development Cullinan Oncology, Oncology, clinical trial, tumours
Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
December 14, 2023Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …
FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment
December 14, 2023Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis
Kyverna Therapeutics has announced that it has gained fast track designation from the US Food and Drug Administration (FDA) for …
Merck and Moderna initiate phase 3 study of NSCLC treatment
December 13, 2023Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial
Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …
PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research
December 13, 2023Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM
PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
December 12, 2023Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …
AstraZeneca to acquire Icosavax for up to $1.1bn
December 12, 2023Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines
AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …
GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
Merck collaborates with Acceleration Consortium for AI experimentation
December 8, 2023Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation
Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …
AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn
December 7, 2023Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition
AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …
ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development
December 7, 2023Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership
ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
